Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

In 2020, Darzalex Faspro (the Sub-Q version) changed the game. The infusion time went from three hours (or an hour and a half ...

A new health initiative seeks to improve maternal care in Marsabit by offering modern facilities, specialised equipment, and ...

As an authorized Starlink dealer, Fly Alliance has been leading the charge in aviation innovation by equipping its Ultra-Long-Range aircraft with Starlink's next-generation satellite connectivity and ...

On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant ...

Retractable Technologies, Inc. announces its EasyPoint® Blood Collection Tube Holder with Needle has received an Innovative Technology designation from Vizient®, the largest healthcare performance ...

SEPTA union members on Sunday voted to authorize a strike as Transport Workers Union Local 234 works to negotiate a new ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease (CTAD) conference, being held in ...

Significant Improvement in the Living Standards of the Poor Through poverty alleviation, there has been a substantial ...

Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications ...

IMUNON Presents Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting – On November 7, 2025, the Company presented translational data from the Phase 2 OVATION 2 ...

Breast cancer is the most common cancer among women in Sri Lanka. Annually, out of approximately 37,000 newly diagnosed ...